The company was founded in 2017 via a $30 million series A funding round from Lilly Asia Ventures, and took on three assets in non-alcoholic steatohepatitis (NASH) programs from Eli Lilly in April 2018.

Terns’ pipeline includes four clinical stage development programs including an allosteric BCR-ABL inhibitor, a THR-β agonist, an FXR agonist, a VAP-1 inhibitor, and a preclinical small-molecule GLP-1 receptor agonist program.